Restem

Name: Restem
Address: 1728 Coral Way Suite 600B, Miami, FL, 33145, US
Telephone: +18004900924

Call Directions Website Contact the business

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Restem, Biotechnology company, 1728 Coral Way Suite 600B, Miami, FL.

RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies for autoimmune, inflammatory, and age-related diseases.

09/25/2026

We’re excited to be at MyoCon in St. Louis!

If you’re attending, be sure to stop by the Restem booth to learn more about our clinical trial for dermatomyositis and polymyositis…. and pick a duck for a chance to win a prize!

We’d love to meet you, answer your questions, and share more about the study. Come say hello!

09/02/2026

Fatigue is a common but often overlooked challenge for people living with Idiopathic Inflammatory Myopathies (IIM). Unlike ordinary tiredness, disease-related fatigue can persist even with adequate rest and may affect concentration, physical activity, work, and everyday routines.

Alongside muscle weakness and other symptoms, fatigue can add to the overall burden of IIM and impact quality of life. Recognizing the broader patient experience is important as research continues to advance new approaches to care.

Learn more about RESTEM and our work in IIM:
https://lnkd.in/eq75CQAx

08/26/2026

At the center of FSHD is a gene called DUX4, which is normally inactive in healthy adult muscle. In FSHD, genetic changes can cause DUX4 to become inappropriately active, contributing to muscle cell damage and progressive weakness. Understanding the biology behind FSHD is helping researchers explore new approaches to addressing this complex disease.

Learn more about RESTEM’s FSHD program:
https://lnkd.in/dcfMzXiH

08/20/2026

Because IIM can affect strength, mobility, and daily function, measuring progress goes beyond any single symptom. Researchers consider multiple aspects of disease activity and physical function to better understand whether a treatment is making a meaningful difference.

In our Phase 1 clinical trial, Restem-L demonstrated clinically meaningful and durable improvements in the Total Improvement Score (TIS), a measure designed to capture improvement across multiple areas of IIM.

As research advances, evaluating outcomes that reflect how patients feel and function remains an important part of developing new therapeutic approaches.

Explore Restem-L and our work in IIM:
https://lnkd.in/eq75CQAx

08/13/2026

One of the distinguishing features of FSHD is asymmetric muscle weakness, meaning one side of the body may be affected more than the other. This asymmetry, along with differences in severity and progression, can make FSHD look different from person to person. Understanding these variations is important to advancing research and exploring new approaches that address the needs of patients living with FSHD.

Explore RESTEM's work in FSHD:
https://lnkd.in/dcfMzXiH

08/06/2026

How much do you know about Idiopathic Inflammatory Myopathies (IIM)? Despite growing awareness, misconceptions about these rare autoimmune diseases remain common. Understanding the facts is an important step toward improving awareness, supporting earlier recognition, and highlighting the continued need for research and innovation.

Explore Restem-L and our work in IIM:
https://lnkd.in/eq75CQAx

07/29/2026

Living with Facioscapulohumeral Muscular Dystrophy (FSHD) often means adapting to changes that extend beyond muscle weakness. As the disease progresses, everyday activities such as lifting objects, reaching overhead, climbing stairs, or maintaining balance may become increasingly challenging. Because FSHD affects each person differently, its impact on mobility, independence, and quality of life can vary significantly.

While there is currently no cure for FSHD, ongoing research continues to improve our understanding of the disease and support the development of new therapeutic approaches aimed at addressing significant unmet medical needs.

Learn more about RESTEM and our development programs: https://lnkd.in/dcfMzXiH

07/22/2026

Continued progress in the understanding of complex muscle disorders is helping shape the future of patient care. While Idiopathic Inflammatory Myopathies (IIM) and Facioscapulohumeral Muscular Dystrophy (FSHD) are distinct conditions with different underlying causes, research across neuromuscular and autoimmune diseases continues to expand our understanding of the biological mechanisms that drive these disorders.

In IIM, the immune system mistakenly attacks healthy muscle tissue, leading to chronic inflammation, muscle weakness, and, in some cases, complications affecting other organs. Although the exact causes of IIM are still being studied, ongoing advances in autoimmune disease research are providing valuable insights that may help inform future therapeutic strategies aimed at addressing underlying disease mechanisms rather than simply managing symptoms. As scientific understanding continues to evolve, it creates new opportunities to explore innovative approaches that may improve outcomes for patients living with IIM.

Learn more about Restem's research in IIM:
https://lnkd.in/eq75CQAx

07/16/2026

Early recognition of Facioscapulohumeral Muscular Dystrophy (FSHD) can play an important role in helping patients access specialized care, supportive therapies, and clinical research opportunities. Because FSHD is a rare genetic muscle disorder, diagnosis can sometimes be delayed, particularly in the early stages when symptoms may be mild or mistaken for other conditions. Increasing awareness among patients, caregivers, and healthcare providers is an important step toward improving care and advancing research.

At Restem, we are conducting a Phase 1/2 clinical trial evaluating Restem-L for FSHD as we continue exploring innovative cell therapy approaches for neuromuscular disorders.

Learn more about our FSHD clinical trial:
https://lnkd.in/dcfMzXiH

07/08/2026

We are committed to advancing next-generation cell therapies designed to modulate the immune system and support the body's natural repair processes. While FSHD and autoimmune diseases such as Idiopathic Inflammatory Myopathies (IIM) are distinct conditions, ongoing research across neuromuscular disorders highlights the importance of exploring innovative approaches for patients with significant unmet medical needs.

Facioscapulohumeral Muscular Dystrophy (FSHD), one of the most common forms of muscular dystrophy, is characterized by progressive muscle weakness that often affects the face, shoulders, and upper arms, impacting mobility, physical function, and quality of life over time.

Although FSHD and IIM have different underlying causes, both underscore the challenges patients face when living with chronic, progressive muscle disorders.

Learn more about RESTEM and our development programs: https://lnkd.in/dcfMzXiH

Address

1728 Coral Way Suite 600B
Miami, FL
33145

Telephone

+18004900924

Website

https://restem.com/, https://www.linkedin.com/company/restemgroup/?viewAsMember=true, https://x.com/restem_us

Alerts

Be the first to know and let us send you an email when Restem posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Restem:

Want your business to be the top-listed engineering company in Miami?